Ss Life Science Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.60 M
- Company Age 8 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.70 M
- Satisfied Charges ₹ 0.70 M
- Revenue Growth 53.07%
- Profit Growth -10.86%
- Ebitda 75.98%
- Net Worth 9.47%
- Total Assets 20.35%
About Ss Life Science
Ss Life Science Private Limited (SLSPL) is a Private Limited Indian Non-Government Company incorporated in India on 13 October 2016 (Eight years and three months 27 days old ). Its registered office is in Varanasi, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.60 M.
The company currently has active open charges totaling ₹3.70 M. The company has closed loans amounting to ₹0.70 M, as per Ministry of Corporate Affairs (MCA) records.
Arpita Das and Saurabh Srivastav serve as directors at the Company.
Company Details
-
Location
Varanasi, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24299UP2016PTC087046
-
Company No.
087046
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
13 Oct 2016
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Ss Life Science?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Arpita Das
|
Whole-Time Director | 21-Dec-2018 | Current |
| Saurabh Srivastav | Director | 16-Aug-2024 | Current |
Financial Performance of Ss Life Science.
Ss Life Science Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 53.07% increase. The company also saw a substantial fall in profitability, with a 10.86% decrease in profit. The company's net worth moved up by a moderate rise of 9.47%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ss Life Science?
In 2023, Ss Life Science had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹3.70 M
₹0.70 M
Charges Breakdown by Lending Institutions
- Canara Bank : 0.37 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 23 Sep 2022 | Canara Bank | ₹3.70 M | Open |
| 25 Sep 2019 | Canara Bank | ₹0.70 M | Satisfied |
How Many Employees Work at Ss Life Science?
Unlock and access historical data on people associated with Ss Life Science, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ss Life Science, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ss Life Science's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
